Structure–activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)-5-{2-[3-(substituted)-1-azetidinyl]-ethyl}-2-piperidones. Part 2: Improving oral absorption-Reference-Cited by-同舟云学术

Structure–activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)-5-{2-[3-(substituted)-1-azetidinyl]-ethyl}-2-piperidones. Part 2: Improving oral absorption

Published:2005-09 Issue:17 Volume:15 Page:3957-3961
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Middleton Donald S.,MacKenzie A. Roderick,Newman Sandra D.,Corless Martin,Warren Andrew,Marchington Allan P.,Jones Barry

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference14 articles.

1. A role of tachykinin NK2 receptor antagonists in the treatment of IBS?

2. Tachykinin NK1receptor antagonists for the control of chemotherapy-induced nausea and vomiting

3. Neurokinin Receptor Antagonists

4. Neurokinin1 Receptor Antagonists as Potential Antidepressants

5. Tachykinin receptor antagonists for asthma and COPD

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recyclable organocatalyst-promoted one-pot Michael/aza-Henry/lactamization reactions for fluorinated 2-piperidinones bearing four stereogenic centres;RSC Advances;2015

2. One-Pot Synthesis of Optically Enriched 2-Piperidinones from Aliphatic Aldehydes and Cyanoacrylamides;Organic Letters;2013-08-08

3. 1-Amino-4,4-difluorocyclohexanecarboxylic acid as a promising building block for drug discovery: design, synthesis and characterization;Tetrahedron;2013-05

4. The small molecule drug discovery process – from target selection to candidate selection;Introduction to Biological and Small Molecule Drug Research and Development;2013

5. Will Modulation of Neuropeptide Receptors Produce the Next Generation of Antipsychotic Drugs? A Focus on the Neurokinin and Neurotensin Systems;Targets and Emerging Therapies for Schizophrenia;2012-06-24